Dunlop A. Sinclair's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Sep 17, 2024
- Accession no.
- 0000950170-24-107411
- Filed
- Sep 17, 2024
- Trade date
- Sep 16, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.34M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dunlop A. SinclairCIK 0001721108 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | Common Stock | SSaleDisposed | −29,476 | $36.09 | −$1,063,788.84 | 107,524 | Indirect | |
| Sep 16, 2024 | Common Stock | SSaleDisposed | −7,524 | $36.79 | −$276,807.96 | 100,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.